Niu et al. suggest that BCL3 is a promising molecular biomarker of paediatric acute myeloid leukaemia with unfavourable prognosis (45), and the use of BCL-3 expression levels has also been proposed to predict response to alkylating agents in glioma (46). The gene discussed is BCL3; the disease is central nervous system cancer.